MANISH SHETH: Open Payments
NPI 1225083272 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,833 in 55 payments from 13 companies in 2025. Trend: 2023 $1,415 · 2024 $1,004 · 2025 $1,833
Food & beverage: $1,833
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 2 | $298 |
| Axsome Therapeutics, Inc. | 12 | $271 |
| Lundbeck LLC | 8 | $215 |
| Janssen Pharmaceuticals, Inc | 5 | $213 |
| Otsuka America Pharmaceutical, Inc. | 6 | $155 |
| ABBVIE INC. | 8 | $154 |
| E.R. Squibb & Sons, L.L.C. | 2 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $121 |
| Janssen Scientific Affairs, LLC | 1 | $90 |
| Brainsway USA INC | 1 | $54 |
Products named: REXULTI, INGREZZA, Auvelity, SPRAVATO, VRAYLAR, COBENFY, TRINTELLIX, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
